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Abstract
Over the last few decades the establishment of nanoparticles as suitable drug carriers with the
transport of drugs across biological barriers such as the gastrointestinal barrier moved into
the focus of many research groups. Besides drug transport such carrier systems are well
suited for the protection of drugs against enzymatic and chemical degradation. The prepara-
tion of biocompatible and biodegradable nanoparticles based on poly(lactic-co-glycolic acid)
(PLGA) is intensively described in literature, while especially nanoparticles with cationic prop-
erties show a promising increased cellular uptake. This is due to the electrostatic interaction
between the cationic surface and the negatively charged lipid membrane of the cells. Even
though several studies achieved the successful preparation of nanoparticles stabilized with
the cationic surfactants such as didodecyldimethylammonium bromide (DMAB), in most
cases insufficient attention was paid to a precise analytical characterization of the nanoparti-
cle system. The aim of the present work was to overcome this deficit by presenting a new per-
spective in the formulation and characterization of DMAB-stabilized PLGA nanoparticles.
Therefore these nanoparticles were carefully examined with regard to particle diameter, zeta
potential, the effect of variation in stabilizer concentration, residual DMAB content, and elec-
trolyte stability. Without any steric stabilization, the DMAB-modified nanoparticles were sensi-
tive to typical electrolyte concentrations of biological environments due to compression of the
electrical double layer in conjunction with a decrease in zeta potential. To handle this problem,
the present study proposed two modifications to enable electrolyte stability. Both polyvinyl
alcohol (PVA) and polyethylene glycol (PEG) modified DMAB-PLGA-nanoparticles were sta-
ble during electrolyte addition. Furthermore, in contrast to unmodified DMAB-PLGA-nanopar-
ticles and free DMAB, suchmodifications led to a lower cytotoxic activity against Caco-2 cells.
In conclusion this study offers a closer and critical point of view on preparation, in vitro and
analytical evaluation of DMAB-stabilized PLGA nanoparticles for the physiological use.
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Introduction
One of the greatest challenges of nanotechnology is the establishment of a suitable nanoparti-
culate carrier system for overcoming physiological barriers like the intestine. Oral administra-
tion is the preferred route of drug delivery because it provides the highest patient convenience
and compliance [1, 2]. There is extensive literature concerning the correlation of oral drug
absorption in humans and drug permeability across Caco-2 cell monolayers [3–5].
Especially in cancer research, many drugs show low bioavailability after peroral administra-
tion due to their poor stability, solubility, and permeability. Therefore, intravenous application
in many cases is unavoidable. However, the encapsulation of such pharmaceutically challeng-
ing molecules within a polymeric nanoparticle matrix results in an increased drug absorption
in targeted tissues or cells and protects the drug from enzymatic and hydrolytic degradation
[6]. Consequently, the development of carrier systems could cause an increase in therapy effi-
ciency and a decrease in negative side effects due to modified drug delivery [7].
Because of its proven biocompatibility and biodegradation, poly (DL-lactic-co-glycolic acid)
(PLGA) is approved by the FDA for therapeutic use in humans and is one of the most success-
ful starting materials for drug carrier preparations [8, 9]. PLGA possesses very low toxicity due
to the fact that it undergoes hydrolysis to the monomers glycolic acid and lactic acid, which are
endogenously metabolized in the human body using the Krebs cycle and eliminated as carbon
dioxide and water [10, 11].
Basically nanoparticles formed of PLGA are prepared in the presence of polyvinyl alcohol
(PVA) as a widely used steric stabilizer. The most described and applied preparation method is
the emulsification-diffusion method, which leads to particle diameters in the range of 150 to
300 nm [12].
The degree of nanoparticle absorption by cells depends on diameter and surface properties
such as surface charge or hydrophobicity, which in turn are associated with the strength of
interaction between the nanoparticles and the cell membrane [13]. The surfactant used in
nanoparticle preparation has a crucial influence on these factors. In the present study, the qua-
ternary ammonium compound didodecyldimethylammonium bromide (DMAB) was used as a
stabilizer because it leads to monodisperse nanoparticle preparations with a diameter of about
100 nm in combination with a stable positive surface charge. Preparing positively charged
PLGA nanoparticles are described to improve cellular uptake and permeation over cellular bar-
riers due to the fact that in contrast to PVA-stabilized systems adsorptive initiated endocytosis
occurs increasingly [13–17].
Nevertheless recent studies illustrated the comparable pronounced cytotoxic activity of
DMAB [18, 19], which is confirmed by our own cell viability screening. Therefore, the residual
DMAB content of the formulation plays an important role for the characterization of the nano-
particle system, a fact that has received very little consideration in previous studies. The cur-
rently available instrumental methods for quantitation of quaternary ammonium surfactants
are very expensive and time-consuming. Thus they are not easily useful in day-to-day labora-
tory work [20, 21]. Hence one goal of this study was to establish a DMAB quantification
method, which not only serves its purpose perfectly in every laboratory but which also is a
very cheap and fast alternative to the complex instrumental methods. Furthermore, we
characterized DMAB-stabilized nanoparticles in due consideration of surfactant content,
diameter, and zeta potential. Special attention was paid to stability under increasing electrolytic
content.
This initial study took a critical look at the characterization and stability of DMAB-stabi-
lized nanoparticles by physico-chemical as well as cell culture analysis. Two new modifications
are proposed to minimize cytotoxicity and optimize electrolyte stability and therefore to enable
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nanoparticle application under physiological conditions in future experiments. These modifi-
cations could be helpful in preparing DMAB-stabilized nanoparticles for therapeutic use.
Materials and Methods
Materials
Poly (DL-lactide-co-glycolide) (PLGA) Resomer RG 502H and Poly(DL-lactide-co-glycolide)-
co-polyethylene glycol diblock Resomer RGP d50155 were obtained from Evonik Industries AG
(Darmstadt, Germany). Polyvinyl alcohol (PVA) 30,000–70,000 Da and didodecyldimethylam-
monium bromide (DMAB) were purchased from Sigma Aldrich (Steinheim, Germany).
For cell culture experiments Dulbecco’s modified Eagle’s medium (DMEM) and all used
supplements were received from Biochrom AG (Berlin, Germany). VECTASHIELDMounting
Media with DAPI (40,6-Diamidin-2-phenylindol) was purchased from Vector Laboratories
Inc. (Burlingname, USA) andWheat germ agglutinin (WGA) AlexaFluor 350 from Life Tech-
nologies (Carlsbad, USA). All other chemicals were obtained from Roth (Karlsruhe, Germany).
Preparation of DMAB-stabilized nanoparticles
Nanoparticles were prepared by a literature described emulsification-diffusion method [14].
Briefly, 100 mg PLGA (Resomer RG 502H) were dissolved in 2.5 mL ethylacetate. The organic
phase was added to a 5 mL aqueous solution containing 1.25, 2.5, 5, or 10 mg/mL DMAB fol-
lowed by emulsification using a high-speed homogenizer at 15,000 rpm for 5 min. The result-
ing o/w emulsion was slowly poured into 5 mL water and stirred overnight at 550 rpm to
remove the organic phase. The nanoparticles were washed with deionized water by threefold
centrifugation (17,000 g, 25 min) and resuspension. This DMAB-stabilized nanoparticles are
hereinafter referred to as PLGA-DMAB-NP.
Physico-chemical characterization of DMAB-stabilized nanoparticles
The nanoparticles were evaluated for mean diameter and for polydispersity index (PDI), a
dimensionless indicator of size distribution, by a Zetasizer (Nano ZS, Malvern Instruments,
Malvern, UK) using the dynamic light-scattering technique. The zeta potential, representing
both surface charge and stability, was also obtained by means of Zetasizer measurement based
on electrophoretic mobility under an electric field.
The resulting particle yield after purification was determined gravimetrically. Therefore an
aliquot (20.0 μl) of the respective nanoparticle sample was put in micro weighing dishes and
dried for 2 h at 80°C until constant weight.
Nanoparticle modifications
When using non-PEGylated PLGA as starting material, modification with PVA was performed
by resuspension of the nanoparticle pellet after the third centrifugation step in aqueous PVA
solution (1% w/v) followed by shaking overnight at 550 rpm. Afterwards, the nanoparticles
were washed once with deionized water by centrifugation and resuspension (referred as
PLGA-DMAB-PVA-NP).
PEG-modified DMAB nanoparticles were prepared similar to PLGA-DMAB-NP, but using
PEGylated PLGA and emulsification for 10 min (PLGA-DMAB-PEG-NP).
Influence of electrolytes on stability
The nanoparticles were titrated using a titration tool (Multi Purpose Titrator MPT-2, Malvern
Instruments, Malvern, UK) with NaCl solution (250 mol/L) to evaluate the influence of
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electrolyte concentration on stability. Mean diameter, PDI, and zeta potential of triplicate
experiments were determined by Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK)
measurements.
Cell culture
Human epithelial colorectal adenocarcinoma cells (Caco-2) were commercially purchased
from Institut für angewandte Zellkultur Dr. Toni Lindl GmbH (Munich, Germany).
The used cultivation medium of the investigated Caco-2 cells was Dulbecco’s modified
Eagle’s medium (DMEM) with the addition of 1% (v/v) non-essential amino acids, 1% (v/v)
penicillin/streptomycin/glutamine, and 10% fetal calf serum (FCS). The cells were subcultured
twice a week with a ratio of 1:3, after reaching 80% confluence, or were used for experiments.
Incubation experiments with nanoparticle formulations or free DMAB were performed using
serum-free DMEM. For cultivation or incubation with substances, the cells were maintained at
37°C and 10% CO2.
Evaluation of intracellular localization by fluorescence microscopy
Fluorescent nanoparticle formulations for localization experiments were prepared by dissolv-
ing 0.4 mg/mL of the fluorescence dye Lumogen F Red 305 in the ethyl acetate solution used
during the nanoparticle preparation. Caco-2 cells were seeded with a density of 5 x 104 cells/
well on Millicell EZ slides (Merck KGaA, Darmstadt, Germany) and were allowed to grow
overnight. This was followed by 4 h incubation at 37°C and 10% CO2 in serum free media with
0.02 mg/mL fluorescence dye-loaded PLGA-DMAB-NP, PLGA-DMAB-PVA-NP, and
PLGA-DMAB-PEG-NP. Cells were washed once with phosphate buffered saline (PBS) and
incubated with a Wheat germ agglutinin AlexaFluor 350 solution (10 μg/mL) for 10 min at
room temperature for membrane staining. Cells were then washed three times with PBS, fixed
in 4% para-formaldehyde for 15 min and washed again with PBS. For nuclear staining, cells
were covered with VECTASHIELDMounting Media with DAPI (Vector Laboratories Inc.,
Burlingname, USA). Samples were analyzed using a IX81 fluorescence microscope (Olympus,
Hamburg, Germany) with filter systems including excitation at 360–370 nm, dichroic mirror
at 400 nm, emission at 426–446 nm for DAPI and Alexa Fluor 350 and excitation at 535–555
nm, dichroic mirror at 565 nm, emission at 570–650 nm for Lumogen F Red 305.
In vitro cell viability
The performed assay is based on the ability of living cells to reduce a water-soluble red dye,
WST-1, to a yellow-colored formazan product by cellular dehydrogenases (Ishiyama et al.,
1993). The nanoparticle formulations used for the study were freeze-dried and resuspended in
serum-free DMEM.
Caco-2 cells were seeded in 96-well plates with a density of 1 x 104 cells/well and incubated
for 48 h. The cells were incubated with DMAB, PLGA-DMAB-NP, PLGA-DMAB-PVA-NP,
and PLGA-DMAB-PEG-NP, respectively, in concentrations ranging between 0.5 and 2,000 μg/
mL. After 24 h the cells were washed twice with PBS solution with calcium and magnesium
and wells were filled with 100 μL serum-free medium.
Absorbance was measured at 460 nm using a microplate reader (Synergy Mx, BioTek
Instruments, US) to obtain the background absorbance in order to minimize the error based
on unspecific light scattering of the nanoparticles. Untreated cells were taken as negative con-
trol with 100% viability, and cells treated with DMSO were used as positive control with 0%
viability.
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After incubation with nanoparticle formulations or free DMAB for 24 hours 10 μLWST-1
were added to each well, followed by further incubation at 37°C for 1 h. EC50 values were calcu-
lated by curve fitting of the cell viability data finally measured at 460 nm (SigmaPlot version
11, Systat Software GmbH, Erkrath, Germany). Measurements were performed six fold in
three passages and results are expressed as mean ± standard deviation (SD).
Spectrophotometric assay of DMAB using bromothymol blue
The developed method to determine residual DMAB content in the nanoparticle suspension
takes advantage of a direct spectrophotometric assay of quaternary ammonium compounds
and is based on the ionic interaction between the cationic quaternary ammonium ion and the
anionic dye bromothymol blue buffered at pH 7.5 [22]. Bromothymol blue solution is com-
posed of 60 mg bromothymol blue dissolved in 100 mL of ethanol. Stock DMAB solution was
prepared by dissolving an accurately weighed amount in water. Working DMAB solutions
were prepared by diluting aliquots of the stock solution to concentrations between 0 and
300 μg/mL.
The assay was performed by mixing 160 μL of the nanoparticle dispersion with 25 μL
NaOH (1 N). The mixture was incubated for 15 min at 60°C under shaking. Then 25 μL HCl,
140 μL bromothymol blue solution, and sufficient phosphate buffer pH 7.5 were added to a vol-
ume of 2.0 mL. The samples were shaken for 1 h at room temperature. After centrifugation at
20,000 g for 10 min to separate the supernatant containing excess bromothymol blue from the
precipitated green DMAB-bromothymol blue complex, the supernatant was diluted with water
at a ratio of 1:1 and measured photometrically at 610 nm. For linear assay calibration 160 μL
DMAB working solutions (0 to 300 μg/mL DMAB) instead of the nanoparticle dispersion were
used.
Validation of this method was performed according to the ICH harmonized tripartite guide-
line “Validation of analytical procedures: Text and Methodology Q2(R1)”. Therefore the
method was tested with pure DMAB and DMAB plus hydrolyzed PLGA in three different
DMAB concentrations covering the specified range for the procedure. The samples were mea-
sured six fold and analyzed as described above.
Statistical methods
All investigations were done in triplicate. The results are presented as average value with stan-
dard deviation. In order to compare independent groups, one way ANOVA was performed
using the software SigmaPlot version 11 (Systat Software GmbH, Erkrath, Germany). A signifi-
cance level of 5% (p 0.05) between the groups was declared as a significant difference ().
With a significant level of 1% (p 0.01) the difference was defined as highly significant ().
For a most highly significant difference () the significance level was 0.1% (p 0.001).
Results
Preparation of DMAB-stabilized nanoparticles
For the preparation of DMAB-stabilized nanoparticles the method described by Bhardwaj et al.
was adopted with suitable modifications [14]. In comparison to PVA-stabilized PLGA nano-
particles described earlier [23] the use of DMAB as a stabilizer led to smaller particles within a
diameter range of about 70 nm to 110 nm in combination with a positive surface charge.
As seen in Table 1, an increased DMAB concentration from 2.5 to 10 mg/mL resulted in a
significant decreasing particle diameter from about 110 nm to 70 nm. All of the nanoparticles
were obtained as monodisperse samples with PDI values between 0.07 and 0.11. In contrast to
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the reduction of particle size the zeta potential increased from +26 mV to +46 mV with increas-
ing DMAB concentration. The particles prepared with the lowest DMAB concentration of 1.25
mg/mL in the aqueous phase were not suitable for purification by centrifugation.
Nanoparticle modifications
In order to increase particle stability two different modifications of the preparation process
were investigated: I. Resuspension of nanoparticles in PVA solution or II. The use of PLGA--
PEG copolymer instead of the established PLGA polymer.
The analysis of PLGA-DMAB-PVA-NP showed, that adsorptive bound nonionic PVA led
to a significant increase in particle diameter. However with a PDI below 0.1 the particle system
remained monodisperse. The coating with PVA also resulted in a decrease of the zeta potential
(Table 1).
At comparable DMAB concentrations the use of PLGA-PEG block copolymer as starting
material led to an increasing diameter of about 100 nm and a PDI higher than 0.1. Only the
application of 10 mg/mL DMAB in the aqueous phase resulted in acceptable nanoparticles
with a diameter of 103.7 ± 2.4 nm and a PDI of 0.13. In contrast to nanoparticles based on
PLGA the usage of the block copolymer led to a decreased zeta potential of +14 mV.
Influence of electrolytes on colloidal stability
As an electrolyte (NaCl) was added to the nanoparticle suspension, the magnitude of the zeta
potential decreased progressively (Fig 1). This caused particle aggregation—as shown in an
increase of the hydrodynamic diameter—of the nanoparticles from 70 nm to about 250 nm
starting at 30 mM electrolyte concentration.
Even though the unmodified PLGA-DMAB-NP were unstable in electrolyte solutions, both
the PLGA-DMAB-PVA-NP and PLGA-DMAB-PEG-NP remained stable under electrolyte
influence. Although the zeta potential decreased rapidly to ±0 mV a constant diameter of
about 110 nm was measured over the whole titration experiment. Taking a closer look at the
diameter curve progression as a function of electrolyte concentration, it was striking to note
that a small increase by about 10 nm occurred for both particle modifications (Fig 2).
Evaluation of intracellular localization by fluorescence microscopy
In the next step the ability of the nanocarriers to enter Caco-2 cells was examined by incuba-
tion with Wheat germ agglutinin AlexaFluor 350 and DAPI in the presence of the various dye-
loaded NP formulations. Fig 3 illustrates that aggregates of unmodified PLGA-DMAB-NP
adhere to the cell surface and could not be removed by repetitive washing steps. In contrast,
Table 1. Physicochemical properties of PLGA-DMAB-NP and PLGA-DMAB-PVA-NP as a function of the DMAB concentration of the aqueous
phase.
DMAB concentration of the aqueous phase [mg/mL] Particle diameter [nm] PDI Zeta potential [mV]
PLGA-DMAB-NP 2.5 107.9 ± 2.9 0.11 ± 0.021 + 26.3 ± 4.8
5 93.5 ± 3.7 0.09 ± 0.010 + 39.1 ± 0.5
10 70.5 ± 1.8 0.07 ± 0.003 + 46.3 ± 4.0
PLGA-DMAB-PVA-NP 2.5 136.3 ± 2.9 0.05 ± 0.016 + 8.4 ± 2.5
5 115.8 ± 4.1 0.09 ± 0.010 + 22.4 ± 2.0
10 95.5 ± 3.5 0.05 ± 0.017 + 20.1 ± 1.0
Results are expressed as mean ± SD (n = 3).
doi:10.1371/journal.pone.0127532.t001
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Fig 1. Electrolyte stability of PLGA-DMAB-NP. Titration of PLGA-DMAB-NP prepared at a DMAB concentration of 10 mg/ml and initial diameter of 70.5
nm ± 1.8 nm and zeta potential of +46.3 ± 4.0 mV with NaCl to 150 mM. Results are expressed as mean of triplicate experiments showing SD. ●Particle
diameter;Δ Zeta potential.
doi:10.1371/journal.pone.0127532.g001
Fig 2. Electrolyte stability of modified NP. Titration of (a) PLGA-DMAB-PVA-NP (initial diameter of 95.5 ± 3.5 nm and zeta potential of +20.1 ± 1.0 mV) and
(b) PLGA-DMAB-PEG-NP (initial diameter of 103.7 ± 2.3 nm and zeta potential of +14.0 ± 7.3 mV) prepared at a DMAB concentration of 10 mg/ml with NaCl
to 150 mM. Results are expressed as mean of triplicate experiments showing SD. ●Particle diameter;Δ Zeta potential.
doi:10.1371/journal.pone.0127532.g002
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the modified PLGA-DMAB-PVA-NP and PLGA-DMAB-PEG-NP did not aggregate and were
internalized by the Caco-2 cells, therefore resulting in a high cellular uptake.
In vitro cell viability
To evaluate the cytotoxic effect of the nanoparticles on human cells, Caco-2 cells were used as a
model cell line. The effect of different nanoparticle formulations and free DMAB on cell viabil-
ity was evaluated in a concentration range from 0.5–2000 μg/mL using the WST-1 assay.
Pure DMAB incubation resulted in a beginning decrease in cell viability above the concen-
tration of 5 μg/mL and an EC50 value of 10 μg/mL. The PLGA-DMAB-NP exhibited a EC50
value of 50 μg/mL and an initial cytotoxicity at about 10 μg/mL (Table 2).
Fig 3. Evaluation of intracellular localization by fluorescence microscopy. Fluorescence visualization of nanoparticle formulations in Caco-2 cells: (A)
control, (B) PLGA-DMAB-NP, (C) PLGA-DMAB-PVA-NP and (D) PLGA-DMAB-PEG-NP. Cell nuclei were stained with DAPI, membranes with WGA
AlexaFluor 350. Nanoparticles are visualized due to incorporated fluorescence dye Lumogen F Red 305.
doi:10.1371/journal.pone.0127532.g003
Table 2. EC50 values (μg/mL) of free DMAB, PLGA-DMAB-NP, PLGA-DMAB-PVA-NP, and PLGA-D-
MAB-PEG-NP in Caco-2 cells.
Composition EC50 [μg/mL]
DMAB 10.6 ± 1.7
PLGA-DMAB-NP 54.8 ± 6.6
PLGA-DMAB-PVA-NP 350.3 ± 80.3
PLGA-DMAB-PEG-NP 996.5 ± 68.0
Results are expressed as mean ± SD (n = 18).
doi:10.1371/journal.pone.0127532.t002
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In contrast to the unmodified NP’s the EC50 values of PLGA-DMAB-PVA-NP and PLGA-D-
MAB-PEG-NP were 7–12 times higher, whereas first signs of cytotoxicity were observed at
100 μg/ml and 500 μg/mL for PLGA-DMAB-PVA-NP and PLGA-DMAB-PEG-NP, respec-
tively. In all screenings the viability declined to 0% for the highest concentration. The EC50 values
obtained showed that in contrast to the PLGA-DMAB-PVA-NP and PLGA-DMAB-PEG-NP
unmodified PLGA-DMAB-NP were found to be cytotoxic to Caco-2 cells (Table 2).
Spectrophotometric assay of DMAB using bromothymol blue
In consideration of the cytotoxic potential of pure or residual DMAB content in NP formula-
tions, the need for a simple quantitation method is obvious. Because of the challenge to detect
the non UV-active DMAB, the developed method takes advantage of the precipitation of a
green complex of the anionic dye bromothymol blue in presence of a cationic quaternary
ammonium compound.
Following the ICH guideline Q2(R1) the proposed method was validated with regard to lin-
earity and accuracy of pure DMAB and DMAB in combination with hydrolyzed PLGA. To
prove linearity a series of DMAB dilutions within the range of 0 and 300 μg/mL were analyzed
as described above and a calibration curve was calculated with a correlation coefficient of
0.9984 (Table 3).
For verification of precision and accuracy test solutions containing DMAB and DMAB plus
hydrolyzed PLGA at three different concentrations (low, medium, high) were prepared and
measured in triplicate. Both the percentage of DMAB recovery and the confidential interval at
a probability value of 5% were calculated (Table 4). At medium (150 μg/mL) and high (280 μg/
Table 3. Statistics of linear regression for the quantification of DMAB by spectrophotometry.
Parameter Spectrophotometric calibration for DMAB
Slope b -0.0025
Standard Error Sb 3.597
Intercept a 1.0094
Standard Error Sa 0.0070
Standard error of estimate Sy,x 0.0108
Correlation coefﬁcient r 0.9984
Number of samples 8
doi:10.1371/journal.pone.0127532.t003
Table 4. Recovery data for the quantification of DMAB by spectrophotometry.
Parameter DMAB DMAB + hydrolyzed PLGA
level level
Low medium high low medium high
(50 μg/mL) (150 μg/mL) (280 μg/mL) (50 μg/mL) (150 μg/mL) (280 μg/mL)
Recovery [%] 102.93 106.12 101.59 95.10 99.75 101.68
S.D. [%] 30.85 3.23 0.96 17.22 1.05 2.61
Conﬁdence interval (p = 95%)
Upper limit [%] 179.57 114.13 103.98 137.87 102.36 108.16
Lower limit [%] 26.29 98.11 99.20 52.33 97.14 95.20
Maximum [%] 138.19 109.83 102.51 114.72 100.54 103.36
Minimum [%] 80.91 103.99 100.59 82.51 98.56 98.67
Number of samples 3 3 3 3 3 3
doi:10.1371/journal.pone.0127532.t004
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mL) DMAB concentration and regardless of the presence of hydrolyzed PLGA the method
showed a recovery in the range of 99.75–106.12%. in combination with small standard devia-
tions as a measure of precision, whereas the method revealed no valid results at low concentra-
tion (50 μg/mL), which is expressed by the high standard deviation and 95% confidence
interval (Table 4). This leads to the conclusion, that the sample solutions must be diluted in a
way, that concentrations within the range of about 150 μg/mL and 280 μg/mL are achieved.
Based on the validated method the different nanoparticle formulations were analyzed for
DMAB content after particle purification. The more DMAB was used for particle preparation
the more DMAB remained in the particle suspension after purification, which is shown by Fig 4.
Discussion
The present study was designed to reveal and overcome several problems in the preparation of
DMAB-stabilized PLGA nanoparticles associated with agglomeration under raising electrolyte
concentration. In principle, PLGA nanoparticles for drug delivery are routinely prepared with
PVA as a stabilizer [24]. The resulting negative zeta potential leads to an electrostatic repulsion
between the particle system and biological membranes with the consequence of a relatively low
cellular uptake or transport over cellular barriers. DMAB is a quaternary ammonium com-
pound with a smaller critical micelle concentration in comparison to PVA, in consequence
smaller and positively charged nanoparticles result. The lowered particle diameter of about 100
nm as well as shift to a positive zeta potential leads to higher particle uptake in comparison to
PVA stabilized nanoparticles as already described in literature [13–17, 25].
Fig 4. Relationship of DMAB content and zeta potential. Residual DMAB content and zeta potential after purification in relation to the used DMAB
concentration of aqueous phase in particle preparation (mean ± SD, n = 3). The shown significances related to the particle diameter.
doi:10.1371/journal.pone.0127532.g004
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In a first step of the present study the influence of the used DMAB concentration on the
physico-chemical parameters of the resulting nanoparticles was evaluated. During particle
preparation the decreased interfacial tension as a function of the initial DMAB concentration
led to smaller emulsion droplets in the primary emulsion during the homogenization step and
to smaller nanoparticles after nanoprecipitation. The quantification of the residual DMAB con-
tent after purification showed that the more DMAB was initially used for particle preparation
the more residual DMAB was quantified in the nanoparticles. Thus more DMAB remained at
the interface between PLGA and water, which correlates with a higher surface charge and a
higher zeta potential (Fig 5).
One of our aims in preparing DMAB-stabilized PLGA nanoparticles was to establish a
nanoparticulate drug carrier system for future oral drug delivery. Therefore the application of a
colloidal system in physiological media for use in cell culture studies or an in vivo set up
requires electrolyte stability. Thus the smallest nanoparticles of about 70 nm in diameter, pre-
pared with an initial DMAB concentration of 10 mg/mL in the aqueous phase, were titrated
with an NaCl solution up to a final salt concentration of 150 mmol/L NaCl to evaluate the
influence of electrolyte content on stability. For unmodified PLGA-DMAB-NP a rapid agglom-
eration even after the addition of minor NaCl concentrations was observed. The stability of the
nanoparticle dispersions and their tendency to agglomerate below a zeta potential of +40 mV
under electrolyte influence can be described within the context of attractive (such as van der
Waals forces) and repulsive forces (such as electrostatic or steric forces) between particles by
using the Derjaguin-Landau-Verwey-Overbeek (DLVO) theory [26]. The small molecule
Fig 5. Schematic representation of electrolyte influence on electrical double layer and resultant zeta potential.
doi:10.1371/journal.pone.0127532.g005
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DMAB leads only to electrostatic but not steric stabilization depending on the thickness of the
electrical double layer surrounding the particles. The first layer consists of fixed DMAB ions of
the aqueous phase, whereas the second layer is a diffuse layer of nonfixed hydrated ions.
Increasing electrolyte concentration results in a compression of the electrical double layer. As a
result, the zeta potential decreases with increasing electrolyte concentration, even though the
particle surface charge (inner Helmholtz plane) may be unchanged (Fig 5). Therefore, below a
specific zeta potential, the repulsive forces are no longer sufficient to avoid particle agglomera-
tion. This is confirmed by the observed agglomeration of PLGA-DMAB-NP after electrolyte
addition. Therefore the suitability of unmodified DMAB-stabilized nanoparticles for physio-
logical applications should be considered critical.
Consequently a steric stabilization of the particles besides pure electrostatic interaction is a
rational approach. For this reason two modifications of the prepared PLGA-DMAB-NP were
established to overcome the detected stability issues under electrolyte influence. On the one
hand a PVA coating strategy was pursued and on the other hand the starting material PLGA
was exchanged against a PLGA-PEG block copolymer. Both used hydrophilic compounds PEG
and PVA provide steric stabilization of particle dispersions by a repulsion effect caused by a
steric mechanism of stabilization involving both enthalpic and entropic contributions [27].
PEG, a linear polyether diol, forms highly hydrated polymer coils on the nanoparticle surface,
which results in a low degree of immunogenicity and antigenicity [28]. In addition to steric sta-
bilization, PEG modifications are known for a rather long time to prevent opsonization and
represent the primary focus of the development of a long blood circulating drug carriers [29].
On the other hand PVA is the emulsifier most commonly used to stabilize PLGA nanoparticles.
It attaches adsorptively on the particle surface and forms an interconnected network with the
polymer at the interface [24]. The titration curves of the modified nanoparticle systems reveal
comparable characteristics. The very first electrolyte application results in a breakdown of the
zeta potential, whereas the nanoparticle diameter remains unaltered at about 100 nm, which is
in contrast to unmodified PLGA-DMAB-NP (Fig 2). The observed slight increase in particle
diameter as a function of electrolyte concentration is probably based on mechanisms of stabili-
zation of hydrogen-bonding hydration through ionic hydration [30]. Therefore, addition of
NaCl leads to a swelling of the polymer chains of PVA and PEG and to a slight increase in par-
ticle diameter without agglomeration.
The results of the electrolyte stability studies were supported by the cellular localization of
the nanoparticles (Fig 3). Hence aggregates of the PLGA-DMAB-NP onto the cell surface
were observed (Fig 3B), whereas both modified nanoparticle systems PLGA-DMAB-PVA-NP
(Fig 3C) and PLGA-DMAB-PEG-NP (Fig 3D) showed a promising cellular internalization
with a even distribution over the whole cell. The electrolytes present in cell culture medium led
to an agglomeration of the non-steric stabilized PLGA-DMAB-NP and therefore to the
observed bright spots. The pictures clearly underline the critical application of solely DMAB
stabilized nanoparticle formulation under physiological conditions.
Furthermore in previous studies a high cytotoxic activity of DMAB for diverse cell types
was demonstrated [18, 19]. This cytotoxic potential was confirmed by our cell culture results
using a WST assay (EC50 = 10 μg/mL). Both free DMAB and PLGA-DMAB-NP showed a high
cytotoxic activity against Caco-2 cells, as a common used model cell line to analyze gastrointes-
tinal absorption. The parameter of cytotoxicity is crucial for further experiments regarding per-
meability of nanoparticles and therefore has to be screened for all preparations. The fact that
PLGA-DMAB-NP showed high cytotoxic potential (EC50 = 50 μg/mL) though DMAB is not
freely available may be attributed to the strong cationic charge on the particle surface. As previ-
ously described, cationic nanoparticles engage in strong ionic interactions with the negatively
charged cell membranes [31]. In contrast, PLGA-DMAB-PVA-NP and
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PLGA-DMAB-PEG-NP are much less cytotoxic. Although further studies are required to iden-
tify mechanisms for the decreased cytotoxicity of PVA and PEG coated nanoparticles, the data
collected suggest that the steric effect of both polymers shields the cells from direct contact to
cytotoxic DMAB on the particle surface.
These results of cell-viability testing clarify the need for a quantitation method for the sur-
factant DMAB in particle systems. Described methods are not feasible without high technical
complexity [20, 32]. Thus one challenge of this work was to establish and validate a simple and
quick method for DMAB determination. This method takes advantage of a complex formation
between the quaternary ammonium compound DMAB with the anionic dye bromothymol
blue buffered at pH 7.5. The direct spectrophotometric assay was developed according to a pre-
vious described method of Lowry (1978) [22] with numerous modifications. In contrast to the
previous study, the precipitated green complex of DMAB and bromothymol blue is separated
from the supernatant containing the surplus bromothymol blue, which is measured spectro-
photometrically at 610 nm. The results of the validation as described previously show that the
method complies with ICH guidelines and thus is suitable for the determination of the DMAB
content in solution and in nanoparticles after purification.
Conclusion
DMAB is an appropriate surfactant for the preparation of small PLGA nanoparticles with a
positive surface charge. However, upon closer examination of the stability under electrolyte
influence, it becomes apparent that PLGA-DMAB-NP are possibly not qualified for application
in physiological media. We have demonstrated that modification with hydrophilic polymers
such as PVA or PEG leads to electrolyte stability and a decreased cytotoxicity against Caco-2
cells. Thus, modified DMAB nanoparticles could be useful in developing a suitable nanoparti-
culate drug carrier for biomedical applications in contrast to solely DMAB stabilized nanopar-
ticle preparations.
This study also proposes a simple, suitable and convenient method for DMAB quantifica-
tion that could be helpful in further studies for a comprehensive characterization of DMAB
containing nanoparticle systems.
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